of February 27, 2026SOURCE BioArctic## 21%[more press release views with Request a Demo]## Also from this source### Number of shares and votes in BioArctic AB (publ) as of February 27, 2026[BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 78,000 Class B shares during February for delivery of shares...]### BioArctic Interim Report for the period October - December 2025[A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqli ...

Inducement Plan[ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...][More Releases From This Source]## Explore[Health Care & Hospitals][Medical Pharmaceuticals][Conference Call Announcements][News Releases in Similar Topics]---- -- ADC Therapeutics to Participate in March Investor Conferences [Accessibility Statement] Skip NavigationLAUSANNE, Switzerland, Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYS ...

Core Viewpoint - Abbott has declared its 409th consecutive quarterly dividend of 63 cents per share, highlighting its long-standing commitment to returning value to shareholders and its status as a member of the S&P 500 Dividend Aristocrats Index [1][1]. Group 1: Dividend Information - The quarterly common dividend of 63 cents per share is payable on May 15, 2026, to shareholders of record as of April 15, 2026 [1]. - Abbott has increased its dividend payout for 54 consecutive years, demonstrating consistent growth in shareholder returns [1]. Group 2: Company Overview - Abbott is a global healthcare leader with a diverse portfolio that includes diagnostics, medical devices, nutritionals, and branded generic medicines [1]. - The company employs approximately 115,000 colleagues and serves customers in over 160 countries [1].

Core Insights - Photocure ASA reported Hexvix®/Cysview® revenues of NOK 135.1 million in Q4 2025, an increase from NOK 128.6 million in Q4 2024, indicating a positive revenue trend [1] - The company achieved a commercial EBITDA of NOK 8.4 million in Q4 2025, up from NOK 3.9 million in Q4 2024, reflecting improved operational efficiency [1] - For 2026, Photocure anticipates product revenue growth between 7% to 11% on a constant currency basis, supported by ongoing operational leverage [1] Financial Performance - Total revenues for Q4 2025 were NOK 136.7 million, down from NOK 141.7 million in Q4 2024, which included a milestone payment [1] - Group EBITDA for Q4 2025 was NOK 1.9 million, compared to NOK 8.5 million in Q4 2024, while EBIT was reported at NOK -5.5 million, down from NOK 1.2 million [1] - Cash and cash equivalents stood at NOK 238.9 million at the end of Q4 2025 [1] Strategic Initiatives - The company installed 7 new Saphira towers in the U.S. during Q4 2025, contributing to a 22% increase in active accounts, totaling 384 [1] - Photocure is expanding its blue light cystoscopy (BLC®) use and has installed 60 Olympus Visera Elite III systems in Europe since Q1 2025 [1] - The partnership with Claritas and other strategic initiatives aim to enhance the company's diagnostic capabilities and expand its market opportunities [1] Growth Drivers - Continued adoption of rigid kits, expansion of mobile BLC, and ongoing equipment upgrades are expected to drive growth in the base business [1] - Potential catalysts for growth include developments in CMS reimbursement, reintroduction of flexible BLC solutions, and a possible FDA reclassification of BLC [1] - The licensing agreement with Asieris for Cevira includes a significant milestone payment upon regulatory approval in China, along with future royalties based on sales [1]

West Announces Quarterly Dividend and Share Repurchase Program [Accessibility Statement] Skip NavigationEXTON, Pa., Feb. 17, 2026 /PRNewswire/ -- On February 16, 2026, the Board of Directors of [West Pharmaceutical Services, Inc.](NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on May 6, 2026 to shareholders of record on April 29, 2026.On February 17, 2026 ...

(4)——0.50.01Other1.10.30.80.01Adjusted (Non-U.S. GAAP)$172.0$33.4$147.8$2.04Twelve Months ended December 31, 2025OperatingprofitIncometaxexpenseNetincomeDilutedEPSReported (U.S. GAAP)$584.9$121.6$493.7$6.79Unallocated items:Restructuring and other charges (1)23.30.922.40.31SmartDose® 3.5mL sale (2)8.41.96.50.09Cost-method investment activity (3)4.5—4.50.06Amortization of acquisition-related intangible assets (4)0.2—2.00.03Other1.10.30.80.01Adjusted (Non-U.S. GAAP)$622.4$124.7$529.9$7.29Three Months ended De ...

Core Points - A class action securities lawsuit has been filed against DexCom, Inc. for alleged securities fraud affecting investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - These design changes allegedly made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The enhancements to the G7's reliability, accuracy, and functionality were reportedly overstated by the defendants [2] - The true scope and severity of the issues with the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [2] - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [2] Group 2: Legal Process - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Insights - Aurora Cannabis Inc. has announced a distribution partnership with Leafio to enhance access to medical cannabis for patients in Australia [1][2] - The partnership aims to provide educational resources for healthcare professionals and improve patient outcomes through a reliable supply chain [2][5] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across multiple regions including Canada, Europe, Australia, and New Zealand [3] - The company offers a diverse portfolio of brands, including MedReleaf, CanniMed, and Whistler Medical Marijuana Co., and is focused on high-quality cannabis products [3] Partnership Details - The agreement allows Leafio to distribute Aurora's medical cannabis products through its nationwide supply chain, which services over 4,000 pharmacies in Australia [2][5] - The partnership is expected to enhance research, product innovation, and clinician education, ultimately benefiting the medical cannabis industry in the region [2][6] Market Impact - This collaboration is positioned to significantly improve access to consistent, high-quality medical cannabis for Australian patients [2][6] - The partnership reflects Aurora's commitment to expanding its leadership in the Australian market and enhancing patient access to medical cannabis [2][6]

Core Insights - Whitehawk Therapeutics, Inc. is focused on oncology therapeutics, utilizing advanced technologies to enhance antibody drug conjugate (ADC) cancer treatments [1][3] - The company will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 12:30 PM ET [1] - A live webcast of the discussion will be available on the company's investor relations website and can be replayed for approximately 30 days [2] Company Overview - Whitehawk Therapeutics specializes in oncology therapeutics, applying advanced technologies to established tumor biology for improved cancer treatment delivery [3] - The company has developed a three-asset ADC portfolio designed to address the limitations of first-generation ADCs, aiming to significantly impact patients with difficult-to-treat cancers [3] - These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement [3]

Group 1 - Solventum will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 2, 2025, at approximately 10:00 a.m. EST [1] - A live and archived replay of the fireside chat will be available on the company's investor website [1] Group 2 - Solventum is focused on enabling better healthcare through innovative solutions at the intersection of health, material, and data science [2] - The company aims to improve patients' lives and empower healthcare professionals [2] Group 3 - Solventum announced a $1 billion share repurchase program approved by its Board of Directors [3] - The company has entered into a definitive agreement to acquire Acera Surgical, a privately held bioscience company [4]